Why Sarepta may not survive current gene therapy crisis 

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m back, and so glad you are, too! 

This week’s newsletter digs further into the Sarepta Therapeutics gene therapy crisis. Read on for an analysis of the company’s very shaky finances, a perspective from Duchenne families caught in the middle, and some thoughts on why CEO Doug Ingram still has a job.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans